Cargando…
Can glypican-3 be a disease-specific biomarker?
BACKGROUND: Glypican-3 (GPC3) is a cell surface-bound proteoglycan which has been identified as a potential biomarker candidate in hepatocellular carcinoma, lung carcinoma, severe pneumonia, and acute respiratory distress syndrome (ARDS). The aim of our review is to evaluate whether GPC3 has utility...
Autores principales: | Chen, Chaolei, Huang, Xiaomin, Ying, Zhaojian, Wu, Dengmin, Yu, Yani, Wang, Xiangdong, Chen, Chengshui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5433957/ https://www.ncbi.nlm.nih.gov/pubmed/28510121 http://dx.doi.org/10.1186/s40169-017-0146-5 |
Ejemplares similares
-
Lipopolysaccharide-induced CCN1 production enhances interleukin-6 secretion in bronchial epithelial cells
por: Shi, Lin, et al.
Publicado: (2017) -
Disease-specific dynamic biomarkers selected by integrating inflammatory mediators with clinical informatics in ARDS patients with severe pneumonia
por: Chen, Chengshui, et al.
Publicado: (2016) -
Can Serum Glypican-3 Be a Biomarker for Effective Diagnosis of Hepatocellular Carcinoma? A Meta-Analysis of the Literature
por: Yang, Sheng-Li, et al.
Publicado: (2014) -
Glypicans
por: Filmus, Jorge, et al.
Publicado: (2008) -
Clinical Utility of Plasma Glypican-3 and Osteopontin as Biomarkers of Hepatocellular Carcinoma
por: Lee, Hyun Jung, et al.
Publicado: (2014)